News
Novo Nordisk Cuts Earning Forecasts Again, Names New CEO
Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday lowered its full-year earnings forecasts again as it unveiled a new chief executive to tackle "recent market challenges".
Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
2h
Novo Nordisk stock crashes after company cuts sales, profit outlook on weight loss drug competition
Shares in Danish drugmaker Novo Nordisk were down nearly 20% in pre-market trading Tuesday morning after the company cuts its ...
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
The pharmaceutical giant said multiple entities were still marketing and selling unbranded versions of its drug despite U.S.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
The U.S. FDA ban on compounded versions of Novo Nordisk's Wegovy has increased its prescriptions by 33%. Despite this, ...
Novo Nordisk has launched its anti-obesity drug Wegovy in India, which has become a key market for the company. Having ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback